$VSCO up 11% pre-market with stronger than expected comps https://t.co/9BuUnKS33M https://t.co/gIml2nLe6R
$VEEV (-3.8% pre) Medtech Dips As One Pockmark Derails Quarterly Sales Beat https://t.co/k6bvB8WWNM
Veeva Announces Collaboration with Global Biotech to Further Accelerate Clinical Trial Innovation $VEEV https://t.co/zVEBjoW92J
Box Inc. reported its fiscal second-quarter 2026 results with earnings per share (EPS) of $0.33, surpassing analyst estimates by $0.02, and revenue of $294 million, exceeding expectations by $3.2 million and marking an 8.9% year-over-year increase. The company's remaining performance obligations (RPO) reached $1.5 billion, up 16% year-over-year on a constant currency basis, with short-term RPO at $812 million, a 12% increase. Billings grew 3% year-over-year, or 6% on a constant currency basis. Box raised its full-year 2026 revenue guidance to between $1.170 billion and $1.175 billion, citing strong momentum driven by AI adoption and doubling enterprise advanced deals. The company also delivered record gross profit and free cash flow, supported by demand for its Intelligent Content Management platform. Meanwhile, Veeva Systems posted fiscal second-quarter 2026 EPS of $1.99, beating estimates by $0.09, and revenue of $789.1 million, a 16.7% increase year-over-year and above consensus forecasts. Veeva's net income reached $200.3 million, with strong performance across all segments, particularly in its AI and Data Cloud offerings within life sciences. The company provided guidance for the third quarter EPS between $1.94 and $1.95 and revenue between $790 million and $793 million, both above analyst expectations. Veeva also announced a collaboration with a global biotech firm to accelerate clinical trial innovation. Despite these results, Veeva's stock dipped 3.8% pre-market following a medtech sales issue. Additionally, VSCO shares rose 11% pre-market on stronger-than-expected comparable sales.